Brief: Paxmedica Announces Positive Top Line Results From Pax-101 Phase 3 African Sleeping Sickness Study
24/07/2023 13:58
July 24 (Reuters) - PaxMedica Inc PXMD.O :
* PAXMEDICA ANNOUNCES POSITIVE TOP LINE RESULTS FROM THE
PAX-101
(INTRAVENOUS SURAMIN) PHASE 3 AFRICAN SLEEPING SICKNESS STUDY,
PAX-HAT-301
* PAXMEDICA INC - STUDY'S PRIMARY ENDPOINT WAS REACHED AND
DEMONSTRATED STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL
RESULTS
* PAXMEDICA INC - EXPECTING TO FILE AN NDA WITH U.S. FOOD
AND
DRUG ADMINISTRATION FOR USE OF PAX-101 TO TREAT STAGE 1 AFRICAN
SLEEPING SICKNESS IN 2024
Source text for Eikon: ID:nGNX4MlnZy
Further company coverage: PXMD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kuvatris Therapeutics
See all newsBrief: PaxMedica Responds To Emergency Request For IV Suramin And Commits To Provide Immediate Access To PAX-101
PaxMedica rises on Malawi's request for access to sleeping sickness drug
Brief: Paxmedica Receives Emergency Request For Iv Suramin From African Health Ministry For Use In Treating Fatal Sleeping Sickness
Brief: PaxMedica Achieves Key Milestone In The Development Of PAX-101 And Provides Update On Potential NDA Submission
Brief: Paxmedica Announces Pricing Of $7.0 Million Public Offering